Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of bevacizumab in HER2-negative inflammatory breast cancer
2008-001807-53Phase 2Completed
- Sponsor
- Unicancer
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in inflammatory breast cancer (IBC), sponsored by Unicancer. Primary endpoint: Pathological complete response rate (Sataloff). Started May 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2008-001807-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001807-53.